Literature DB >> 21946215

Molecular properties of TAR DNA binding protein-43 fragments are dependent upon its cleavage site.

Yoshiaki Furukawa1, Kumi Kaneko, Nobuyuki Nukina.   

Abstract

Aggregation of TAR DNA binding protein-43 (TDP-43) is a hallmark feature of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Under pathogenic conditions, abnormal cleavage of TDP-43 produces the phosphorylated C-terminal fragments (CTFs), which are enriched in neuronal inclusions; however, molecular properties of those TDP-43 fragments remain to be characterized. Here we show distinct degrees of solubility and phosphorylation among fragments truncated at different sites of TDP-43. Truncations were tested mainly within a second RNA recognition motif (RRM2) of TDP-43; when the truncation site was more C-terminal in an RRM2 domain, a TDP-43 CTF basically became less soluble and more phosphorylated in differentiated Neuro2a cells. We also found that cleavage at the third β-strand in RRM2 leads to the formation of SDS-resistant soluble oligomers. Molecular properties of TDP-43 fragments thus significantly depend upon its cleavage site, which might reflect distinct molecular pathologies among sub-types of TDP-43 proteinopathies.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21946215     DOI: 10.1016/j.bbadis.2011.09.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Structural Rearrangement upon Fragmentation of the Stability Core of the ALS-Linked Protein TDP-43.

Authors:  Brittany R Morgan; Jill A Zitzewitz; Francesca Massi
Journal:  Biophys J       Date:  2017-08-08       Impact factor: 4.033

2.  Neurodegeneration-associated protein fragments as short-lived substrates of the N-end rule pathway.

Authors:  Christopher S Brower; Konstantin I Piatkov; Alexander Varshavsky
Journal:  Mol Cell       Date:  2013-03-14       Impact factor: 17.970

3.  Folding of the RNA recognition motif (RRM) domains of the amyotrophic lateral sclerosis (ALS)-linked protein TDP-43 reveals an intermediate state.

Authors:  Brian C Mackness; Meme T Tran; Shannan P McClain; C Robert Matthews; Jill A Zitzewitz
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

4.  UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination.

Authors:  Friederike Hans; Fabienne C Fiesel; Jennifer C Strong; Sandra Jäckel; Tobias M Rasse; Sven Geisler; Wolfdieter Springer; Jörg B Schulz; Aaron Voigt; Philipp J Kahle
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

5.  Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).

Authors:  Eva Bentmann; Manuela Neumann; Sabina Tahirovic; Ramona Rodde; Dorothee Dormann; Christian Haass
Journal:  J Biol Chem       Date:  2012-05-04       Impact factor: 5.157

6.  Prion-like C-Terminal Domain of TDP-43 and α-Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils.

Authors:  Shailendra Dhakal; Courtney E Wyant; Hannah E George; Sarah E Morgan; Vijayaraghavan Rangachari
Journal:  J Mol Biol       Date:  2021-03-24       Impact factor: 5.469

Review 7.  Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.

Authors:  Alistair Wood; Yuval Gurfinkel; Nicole Polain; Wesley Lamont; Sarah Lyn Rea
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 8.  Molecular, functional, and pathological aspects of TDP-43 fragmentation.

Authors:  Deepak Chhangani; Alfonso Martín-Peña; Diego E Rincon-Limas
Journal:  iScience       Date:  2021-04-21

Review 9.  TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.

Authors:  Emma L Scotter; Han-Jou Chen; Christopher E Shaw
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

10.  Inhibition of TDP-43 aggregation by nucleic acid binding.

Authors:  Yi-Chen Huang; Ku-Feng Lin; Ruei-Yu He; Pang-Hsien Tu; Jiri Koubek; Yin-Chih Hsu; Joseph Jen-Tse Huang
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.